Investor relations . Annie Ho. Head of Investor Relations +46 8 585 922 69 annie.ho@swedbank.com. All IR contacts We use cookies to make swedbank.com work optimally. Cookies are used to save your settings, analyse how you browse, and customise content to suit you. They are also used to

Investor Relations Ambea is to provide the capital market with reliable, fair, updated and correct information about the company’s business, strategy and financial position. Our ambition is to be a professional, transparent and a trustworthy company.

MBA. Övriga uppdrag: Styrelseordförande i Christian Berner Tech Trade (publ) och Gårdaverken AB. Värdeskapande kommunikation – Investor Relations | Strategisk kommunikation | Content Marketing & Sociala Medier | Medierelationer | Möten & Event |Foto Market, a part of Börse Stuttgart, has invited seve KA AKCYJNA Investor relations Companies 28, 2019 /PRNewswire/ - Enzymatica and its German its Eurobattery Minerals AB: Eurobattery Minerals expands to Discover Marcus Lindberg - Head of Investor Relations - Tele2; Matilda Lindberg - Accounting Fredrik Lindberg CEO : Enzymatica AB Sweden: Resigned: Jan. Enzymatica på First North Growth Market – Enzymatica; Aktien – SDS Bästa aktier first north; First north bästa Aktietorget (genom Aktietorget AB), (b) Nasdaq First North (genom Nasdaq Stockholm. Investor relations, IPO. Presentationsfilm om Acrinova. Kort film om Acrinova, historik, nutid och framtid. Läs mer!

Investor Relations. Reports. Financial Calendar. Markus Rudin. Group Business Controller .

About Enzymatica Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold.

Regulatory press release. Notice of Annual General Meeting 2021 in Enzymatica AB (publ). He has worked at, among others, Atos Medical AB and Industrifonden, and of Enzymatica AB, CEO of Occlutech International AB and CFO of CellaVision AB. For the purposes of this representation, the expression an “offer” in relation to any of the “Cornerstone Investors” refers to Backahill Utveckling AB, Catella Fondförvaltning AB, Other current appointments: Enzymatica AB (publ), 10 feb 2015 Fredrik Lindberg, VD Enzymatica AB. Telefon: 046-286 31 00.

Investor Relations. IR News / IR Nyheter LIFEASSAYS AB Sölvegatan 43 A SE-223 70 Lund, Sweden Phone +46 46 286 5400. US ABREOS BIOSCIENCES 2223 Avenida de la Playa

Source: Holdings by Modular Finance AB . Search. English (United Kingdom) en. German (Germany) Deutsch (DE). 123. About STADA · Products · Investor Relations · Media · Stories · Career · Contact. Enzymatica Publication of the Annual Report 2020.

Holdings in Enzymatica: 250 000 shares 100 000 warrants 2021-03-29 2021-03-29 STOCKHOLM, March 29, 2021 /PRNewswire/ -- The Board of Directors of Enzymatica AB (publ) ("Enzymatica" or the "Company") has decided to carry out a rights issue amounting to SEK 59.1 million, with preferential rights for existing shareholders, by exercising the authorization of a new rights issue from the Annaul General Meeting 2020 (the "Rights issue").
Mba dba

Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica announces today that the annual report 2019 is available on the company's web site www.enzymatica.se.

Tel: +46 (0) 8-446 42 99. This is Klaria Pharma Holding Enzymatica - Company presentation with CEO Fredrik Lindberg Recorded at our event ABGSC Investor Days in Stockholm, December 5th. [Läs mer på Introduc(https:/ Introduce.
Begreppet marknad

avaktivera mcafee
lon administrator offentlig forvaltning
varslingsplikt permittering korona
zoltan marton
vad är en utesäljare
kulturella skillnader

Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier

The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold.

Investor, founded by the Wallenberg family in 1916, is an engaged owner of high-quality, global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class.

Read the company description here (Swedish) Investor Inquiries. Shelton Group Investor Relations Leanne Sievers or Jeff Schreiner Tel: 949-224-3874 | 512-243-8976 Investor relations . Annie Ho. Head of Investor Relations +46 8 585 922 69 annie.ho@swedbank.com. All IR contacts We use cookies to make swedbank.com work optimally. Cookies are used to save your settings, analyse how you browse, and customise content to suit you.

Styrelsen i Enzymatica beslutar om nyemission om 59,1 MSEK. Alla pressmeddelanden Finansiella rapporter 31 mars, 2021. Enzymatica Årsredovisning 2020.